Non-Insulin Therapies for Diabetes Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- 99S4144617
- 160 Pages
- December 2020
- Healthcare
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Non-Insulin Therapies for Diabetes market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Non-Insulin Therapies for Diabetes market segmented into
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Based on the end-use, the global Non-Insulin Therapies for Diabetes market classified into
Hospital Pharmacy
Retail Pharmacies
Online Pharmacy
Others
Based on geography, the global Non-Insulin Therapies for Diabetes market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Pfizer
Jiangsu Hengrui Medicine
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL NON-INSULIN THERAPIES FOR DIABETES INDUSTRY
2.1 Summary about Non-Insulin Therapies for Diabetes Industry
2.2 Non-Insulin Therapies for Diabetes Market Trends
2.2.1 Non-Insulin Therapies for Diabetes Production & Consumption Trends
2.2.2 Non-Insulin Therapies for Diabetes Demand Structure Trends
2.3 Non-Insulin Therapies for Diabetes Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Alpha-glucosidase Inhibitors
4.2.2 Amylin Agonists
4.2.3 Biguanides
4.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
4.2.5 Glinides / Meglitinides
4.2.6 GLP-1 Analogs / GLP-1 Agonists
4.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
4.2.8 Sulfonylureas
4.2.9 Thiazolidinediones
4.2.10 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital Pharmacy
4.3.2 Retail Pharmacies
4.3.3 Online Pharmacy
4.3.4 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Alpha-glucosidase Inhibitors
5.2.2 Amylin Agonists
5.2.3 Biguanides
5.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
5.2.5 Glinides / Meglitinides
5.2.6 GLP-1 Analogs / GLP-1 Agonists
5.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
5.2.8 Sulfonylureas
5.2.9 Thiazolidinediones
5.2.10 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital Pharmacy
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacy
5.3.4 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Alpha-glucosidase Inhibitors
6.2.2 Amylin Agonists
6.2.3 Biguanides
6.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
6.2.5 Glinides / Meglitinides
6.2.6 GLP-1 Analogs / GLP-1 Agonists
6.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
6.2.8 Sulfonylureas
6.2.9 Thiazolidinediones
6.2.10 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital Pharmacy
6.3.2 Retail Pharmacies
6.3.3 Online Pharmacy
6.3.4 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Alpha-glucosidase Inhibitors
7.2.2 Amylin Agonists
7.2.3 Biguanides
7.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
7.2.5 Glinides / Meglitinides
7.2.6 GLP-1 Analogs / GLP-1 Agonists
7.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
7.2.8 Sulfonylureas
7.2.9 Thiazolidinediones
7.2.10 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital Pharmacy
7.3.2 Retail Pharmacies
7.3.3 Online Pharmacy
7.3.4 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Alpha-glucosidase Inhibitors
8.2.2 Amylin Agonists
8.2.3 Biguanides
8.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
8.2.5 Glinides / Meglitinides
8.2.6 GLP-1 Analogs / GLP-1 Agonists
8.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
8.2.8 Sulfonylureas
8.2.9 Thiazolidinediones
8.2.10 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital Pharmacy
8.3.2 Retail Pharmacies
8.3.3 Online Pharmacy
8.3.4 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Alpha-glucosidase Inhibitors
9.2.2 Amylin Agonists
9.2.3 Biguanides
9.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
9.2.5 Glinides / Meglitinides
9.2.6 GLP-1 Analogs / GLP-1 Agonists
9.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
9.2.8 Sulfonylureas
9.2.9 Thiazolidinediones
9.2.10 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital Pharmacy
9.3.2 Retail Pharmacies
9.3.3 Online Pharmacy
9.3.4 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 GSK
10.1.2 Eli Lilly
10.1.3 Sumitomo Dainippon Pharma
10.1.4 Intarcia Therapeutics
10.1.5 Servier
10.1.6 Jiangsu Hansoh Pharmaceutical
10.1.7 Novo Nordisk
10.1.8 Emisphere
10.1.9 Uni-Bio Science Group
10.1.10 Takeda
10.1.11 3SBio
10.1.12 Merck
10.1.13 Dong-A Pharmaceutical
10.1.14 Luye Pharma Group
10.1.15 Eurofarma
10.1.16 Geropharm
10.1.17 Alkem Labs
10.1.18 SatRx
10.1.19 Pfizer
10.1.20 Jiangsu Hengrui Medicine
10.2 Non-Insulin Therapies for Diabetes Sales Date of Major Players (2017-2020e)
10.2.1 GSK
10.2.2 Eli Lilly
10.2.3 Sumitomo Dainippon Pharma
10.2.4 Intarcia Therapeutics
10.2.5 Servier
10.2.6 Jiangsu Hansoh Pharmaceutical
10.2.7 Novo Nordisk
10.2.8 Emisphere
10.2.9 Uni-Bio Science Group
10.2.10 Takeda
10.2.11 3SBio
10.2.12 Merck
10.2.13 Dong-A Pharmaceutical
10.2.14 Luye Pharma Group
10.2.15 Eurofarma
10.2.16 Geropharm
10.2.17 Alkem Labs
10.2.18 SatRx
10.2.19 Pfizer
10.2.20 Jiangsu Hengrui Medicine
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
Table Non-Insulin Therapies for Diabetes Product Type Overview
Table Non-Insulin Therapies for Diabetes Product Type Market Share List
Table Non-Insulin Therapies for Diabetes Product Type of Major Players
Table Brief Introduction of GSK
Table Brief Introduction of Eli Lilly
Table Brief Introduction of Sumitomo Dainippon Pharma
Table Brief Introduction of Intarcia Therapeutics
Table Brief Introduction of Servier
Table Brief Introduction of Jiangsu Hansoh Pharmaceutical
Table Brief Introduction of Novo Nordisk
Table Brief Introduction of Emisphere
Table Brief Introduction of Uni-Bio Science Group
Table Brief Introduction of Takeda
Table Brief Introduction of 3SBio
Table Brief Introduction of Merck
Table Brief Introduction of Dong-A Pharmaceutical
Table Brief Introduction of Luye Pharma Group
Table Brief Introduction of Eurofarma
Table Brief Introduction of Geropharm
Table Brief Introduction of Alkem Labs
Table Brief Introduction of SatRx
Table Brief Introduction of Pfizer
Table Brief Introduction of Jiangsu Hengrui Medicine
Table Products & Services of GSK
Table Products & Services of Eli Lilly
Table Products & Services of Sumitomo Dainippon Pharma
Table Products & Services of Intarcia Therapeutics
Table Products & Services of Servier
Table Products & Services of Jiangsu Hansoh Pharmaceutical
Table Products & Services of Novo Nordisk
Table Products & Services of Emisphere
Table Products & Services of Uni-Bio Science Group
Table Products & Services of Takeda
Table Products & Services of 3SBio
Table Products & Services of Merck
Table Products & Services of Dong-A Pharmaceutical
Table Products & Services of Luye Pharma Group
Table Products & Services of Eurofarma
Table Products & Services of Geropharm
Table Products & Services of Alkem Labs
Table Products & Services of SatRx
Table Products & Services of Pfizer
Table Products & Services of Jiangsu Hengrui Medicine
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Non-Insulin Therapies for Diabetes Market Forecast (Million USD) by Region 2021f-2026f
Table Global Non-Insulin Therapies for Diabetes Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Non-Insulin Therapies for Diabetes Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Non-Insulin Therapies for Diabetes Market Forecast (Million USD) Share by Demand 2021f-2026f
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
